Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
News|Podcasts|March 19, 2026
Pharma Pulse: FDA Approval of Icotyde for Plaque Psoriasis and CCT’s MedAssure Debut
Author(s)Stephen Appezzato
In today's Pharma Pulse, the FDA approves Icotyde as the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis, while Cold Chain Technologies prepares to debut its MedAssure orchestration platform at LogiPharma 2026
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.
- Cold Chain Technologies (CCT) will debut its
MedAssure orchestration platform at LogiPharma 2026. According to CCT, MedAssure provides proactive, data-driven intelligence to optimize cold chain performance. Beyond reducing logistics costs, the platform is engineered to support industry decarbonization goals by minimizing the environmental burden of wasted products. - In other news, The FDA has
approved Icotyde as the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis in adults and adolescents. This once-daily pill blocks the IL-23 receptor, offering a systemic treatment option that avoids the injection-based administration typical of other IL-23 biologics. In superiority studies, approximately 70% of patients achieved clear or almost clear skin at week 16.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.
In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Early Development Decisions Shape Commercial Readiness for Biologics
2
FAQ: What Comes Next for the 340B Rebate Pilot
3
Why Early, Big-Picture Planning Is Key to Execution Across the CGT Lifecycle
4
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
5